To bolster its life sciences and diagnostics portfolios, Novo Holdings has made another major investment to acquire BBI Group.

Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune

Private Company Edition: Venture capital mega-rounds continue to add up, including recent financings for Connect Biopharma ($115m) and Synthego ($100m). Also, Civilization Ventures closed a new $35m fund and Triumvira launched with $55m.

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.